Ủy viên đại diện Glass Lewis khuyến nghị cổ đông Warner Bros bỏ phiếu ủng hộ thương vụ Paramount

"Forced divestitures to satisfy DOJ could eliminate the merger’s synergy case while ticking fees accumulate—a scenario Glass Lewis’s neutrality may be hedging."

ChatGPT and Grok both frame DOJ scrutiny as negotiable—divestitures, behavioral remedies. But nobody’s quantified what that costs. If DOJ forces HBO or Paramount+ divestiture to clear, WBD shareholders get cash today but lose the synergy thesis entirely. The $25M annual ticking fee assumes Q3 close; if regulatory remedies drag into 2025, that fee balloons and the deal economics invert. Glass Lewis’s ‘neutral’ stance may reflect this unpriced tail risk.

"The ticking fee acts as a strategic pressure tactic against regulatory delays rather than just a passive cost of doing business."

Claude and Gemini are underestimating the leverage of the 25-cent ticking fee. This isn't just a cost; it's a ‘poison pill’ for regulators. By attaching a recurring penalty to delays, WBD and Paramount create a ‘deal-certainty’ premium that pressures the DOJ to act quickly or risk being blamed for destroying shareholder value during a prolonged review. If the DOJ forces divestitures, they likely target linear assets (CBS/CNN), which actually accelerates the pivot to a higher-margin streaming-only model.

"The ticking fee pressures the parties, not the DOJ, so it likely increases the chance of faster but riskier remedies or litigation rather than forcing antitrust approval."

The ticking fee isn't a regulatory ‘poison pill’—it’s a private incentive that can press the parties, not the DOJ. Antitrust enforcers answer to law and precedent, political oversight, and internal timelines; they won't accelerate relief simply to avoid a corporate penalty. More likely: the fee raises pressure to accept narrower divestitures or riskier remedies, increasing litigation probability and post-close execution risk—something nobody’s priced.

"DOJ ignores ticking fees per precedent, heightening WBD’s debt-servicing risk in prolonged reviews."

Gemini’s ‘poison pill’ claim ignores DOJ precedent: Microsoft paid billions in ticking fees during 18-month Activision review yet faced full scrutiny before CMA carve-outs. Here, subpoenas target core studio consolidation; delays compound WBD’s $40B debt (~$500M annual interest at 5% avg), eroding the cash inflow thesis without priced remedies.